HGH Fragment 176-191

Human clinical Weight Loss & Metabolism 3 sources

HGH Fragment 176-191 is a modified synthetic peptide derived from amino acids 176-191 of the human growth hormone (HGH) polypeptide. Research indicates it mimics the way natural HGH regulates fat metabolism, stimulating fat breakdown and inhibiting fat formation, but without the adverse effects on blood sugar or cell proliferation seen with unmodified HGH.

01Dosing reference

Amount

250-500 mcg/day

Frequency

1-2x daily (often fasted, before cardio or bed)

Cycle

8-12 weeks

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Lipolytic Pathway Activation

The peptide binds to beta-3 adrenergic receptors or similar pathways to stimulate lipolysis.

Metabolic Action

It increases the breakdown of stored fat (lipolysis) and inhibits the conversion of non-fatty foods into body fat (lipogenesis).

Targeted Fat Loss

This results in a reduction of adipose tissue without affecting insulin sensitivity or increasing IGF-1 levels.

03Human evidence

Increased weight loss and fat oxidation in obese subjects.

Clinical trials on obese patients (often using the closely related AOD9604 variant) showed increased fat loss compared to placebo over a 12-week period.

No negative impact on insulin resistance or blood glucose.

Studies demonstrated that unlike full-length HGH, the fragment does not induce hyperglycemia or reduce insulin sensitivity in human subjects.

04Preclinical evidence

Significant reduction in body fat in obese animal models.

Animal models showed targeted fat reduction without altering food intake, growth, or inducing insulin resistance.

Potential for cartilage repair and regeneration.

Some animal studies suggest that intra-articular injection of the peptide may promote cartilage regeneration in osteoarthritis models.

05What is known vs. unknown

Reasonably established

Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation).
Does not impact insulin sensitivity or blood glucose levels, unlike full-length HGH.
Does not stimulate IGF-1 production, avoiding cellular proliferation risks.
Often researched for its potential in treating obesity and metabolic disorders.

Unknowns & limits

Long-term safety and efficacy in diverse human populations remain under-researched.
Optimal dosing protocols and delivery methods for maximum bioavailability are still debated.
The exact receptor binding mechanism is not as fully mapped as other metabolic peptides.

06Safety & regulatory context

Regulatory statusHGH Fragment 176-191 is generally considered to have a favorable safety profile in research settings, lacking the diabetogenic and proliferative side effects of full-length HGH. Common side effects reported in studies include mild injection site reactions such as redness or pain. It is not FDA-approved for human use and is classified as an investigational research chemical. Furthermore, it is banned by the World Anti-Doping Agency (WADA) for use in competitive sports.

07Compared with Human Growth Hormone (HGH)

HGH Fragment 176-191 vs. Human Growth Hormone (HGH)

Key difference

HGH Fragment 176-191 isolates the fat-burning properties of HGH without affecting IGF-1 levels or insulin sensitivity.

When researchers discuss each

HGH is discussed for overall growth, recovery, and anti-aging, while the fragment is specifically targeted for fat loss and metabolic regulation.

08Glossary

Lipolysis

The metabolic process of breaking down lipids (fats) into free fatty acids and glycerol.

Lipogenesis

The metabolic formation of fat from non-fat sources.

IGF-1

Insulin-like Growth Factor 1, a hormone that manages the effects of growth hormone in the body and promotes cell growth.

09Knowledge check

Q1What is the primary advantage of HGH Fragment 176-191 over full-length HGH in research?

Q2Which biological process does HGH Fragment 176-191 primarily inhibit?

Q3Which documented limitation is most important to consider when interpreting the current human research on HGH Fragment 176-191?

Q4When researchers explicitly compare HGH Fragment 176-191 with full-length HGH, for which application is the fragment most specifically studied?

Q5Which statement best describes the safety and regulatory status of HGH Fragment 176-191 as provided in the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.